Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Asia Pacific Prostate Cancer Conference /
Insights into mCRPC in China, Thailand and Indonesia - expert discussion

1st - 2nd Mar 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.03.14
Views: 3355

Prof Rainy Umbas, Prof Narin Voravud and Prof Li Ping Xie

Speaking to ecancer from the Academy for Cancer Education (ACE) 3rd Asia Pacific Prostate Cancer Conference (APPCC) in Shanghai, Prof Rainy Umbas from the University of Indonesia, Jakarta, Indonesia, interviews Prof Narin Voravud from Chulalongkorn University Hospital, Bangkok, Thailand, and Prof Li Ping Xie from Zhejiang University School of Medicine, Hangzhou, China.

The experts first comment on local available treatment choices for mCRPC in their respective countries. The importance of diagnosing prostate cancer sooner is emphasised by the experts, since a high proportion are not found until the late stage disease at present.

The experts discuss how local policies differ from guidelines in Europe and America due to the lack of availability currently of newer drugs, such as abiraterone. However, the importance of treating patients individually, according to the evidence available and to international standards, was stressed.

They then discuss new treatments on the horizon in their respective countries, e.g. radium-223, and how these will affect treatment decision-making. The promise of benefit that enzalutamide may bring to prostate cancer care in the region is emphasised, although the challenges of sequencing are raised.

The experts finally discuss how treatment choices should be made, including in the growing number of elderly patients in the region, and the importance of multi-disciplinary teams in treatment choices.

This video is sponsored by an educational grant from Janssen Asia Pacific, pharmaceutical companies of Johnson & Johnson

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation